These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
675 related articles for article (PubMed ID: 9882851)
1. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?]. Luño J; Valderrábano F An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851 [No Abstract] [Full Text] [Related]
2. [Control of arterial pressure in diabetic nephropathy]. Luño J; García de Vinuesa S Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304 [No Abstract] [Full Text] [Related]
3. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. Bakris GL; Toto RD; McCullough PA J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors. Crook ED; Preddie DC Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155 [TBL] [Abstract][Full Text] [Related]
5. Best practice for hypertensive patients with kidney disease. de Zeeuw D Hosp Med; 2003 Feb; 64(2):96-100. PubMed ID: 12619337 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Hughes DB; Britton ML Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022 [TBL] [Abstract][Full Text] [Related]
8. ACE inhibitors as a shield against diabetic nephropathy. Materson BJ Arch Intern Med; 1996 Feb; 156(3):239-40. PubMed ID: 8572832 [No Abstract] [Full Text] [Related]
9. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]
10. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control]. Shionoiri H; Yasuda G; Takizawa T; Shionoiri F Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741 [No Abstract] [Full Text] [Related]
11. The role of angiotensin receptor blockers in diabetic nephropathy. Sharma AM; Weir MR Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421 [TBL] [Abstract][Full Text] [Related]
12. Nephropathy in patients with type 2 diabetes mellitus. Ritz E; Orth SR N Engl J Med; 1999 Oct; 341(15):1127-33. PubMed ID: 10511612 [No Abstract] [Full Text] [Related]
13. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. Weir MR Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817 [TBL] [Abstract][Full Text] [Related]
15. Albuminuria: a target for treatment of type 2 diabetic nephropathy. de Zeeuw D Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686 [TBL] [Abstract][Full Text] [Related]
16. [Prediction, screening and treatment of renal complications of diabetes]. Marre M; Larger E Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120 [TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of diabetic renal disease: focus on losartan. Rayner B Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842 [TBL] [Abstract][Full Text] [Related]
18. Hypertension arm of ADVANCE defines extent of renal protection using perindopril/indapamide in type 2 diabetics. Cardiovasc J Afr; 2008; 19(4):226. PubMed ID: 18776973 [No Abstract] [Full Text] [Related]
19. [Diabetic nephropathy]. Morcos M; Zeier M; Schwenger V Dtsch Med Wochenschr; 2007 May; 132(19):1039-42. PubMed ID: 17476634 [No Abstract] [Full Text] [Related]